Menu
No results found.
Weekly Share Price & Valuation Overview
Vitrafy Life Sciences Limited provides cryopreservation solutions in Australia. Its cryopreservation technology improves the cell survival of cryopreserved biological materials, such as blood platelets used to treat trauma patients, t cells used in cancer treatments, and animal sperm used in breeding and farming. The company provides smart freezing device, smart thawing device, and LifeChain, a sample quality management software platform, as well as smart blood bag and sperm packaging solution. It serves animal genetics and animal reproduction suppliers; blood platelets organizations, biobanks, and points of care; and human cell and gene therapies markets. The company has research and collaboration agreement with CSL Innovation Pty Ltd, US Army Institute of Surgical Research, Select Sires, Inc. and a Huon Aquaculture Company Pty Ltd. Vitrafy Life Sciences Limited was incorporated in 2017 and is based in Melbourne, Australia.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Market Cap Total equity value of the company (share price × shares outstanding).
- AUD 102.16M
- Enterprise Value Operating value: market cap + total debt − cash.
- AUD 82.98M
- Total Revenue (TTM) Estimated Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- AUD 1.47M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- AUD 0.02
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -0.73
- Shares Outstanding
- 63.85M
- Float Shares
- 34.51M
- Implied Shares Outstanding
- 65.84M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-28.32%
- ROA Return on assets: net income ÷ total assets.
-
-46.76%
- ROE Return on equity: net income ÷ shareholder equity.
-
-15.70%
- Revenue Growth Year-over-year revenue growth.
-
-63.70%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 7.77
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 1.36
- Total Cash Cash and equivalents.
- AUD 19.57M
- Total Debt Short + long-term interest-bearing debt.
- AUD 392.36K
- Net Debt Net Cash Total debt − cash (negative = net cash).
- AUD -19.18M
- Total Revenue (TTM) estimated from Revenue per Share × Shares due to feed inconsistency.
- EBITDA & EBITDA margin suppressed (implausible vs revenue or not meaningful for financials).
- Gross Profit hidden for financial institutions (often redundant with revenue).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.